Lifecore Biomedical Q3 Adj. EPS $(0.22) Misses $(0.13) Estimate, Sales $27.60M Miss $28.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Lifecore Biomedical (NASDAQ:LFCR) reported Q3 adjusted losses of $(0.22) per share, missing the $(0.13) estimate by 69.23%. Sales were $27.60M, missing the $28.00M estimate by 1.43%, compared to $37.40M in the same period last year.
June 01, 2023 | 11:25 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lifecore Biomedical's Q3 adjusted losses and sales missed analyst estimates, with losses of $(0.22) per share and sales of $27.60M.
Lifecore Biomedical's Q3 results show a significant miss in both adjusted losses and sales compared to analyst estimates. The adjusted losses were 69.23% higher than expected, and sales were 1.43% lower than expected. This negative performance is likely to have a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100